(1->4)-beta-D-glucan multiple interactions EXP 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of LIPG mRNA CTD PMID:36331819 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane decreases expression ISO RGD:1321819 6480464 o, p'-DDT results in decreased expression of LIPG mRNA CTD PMID:18204070 1,2-dichloroethane decreases expression EXP 6480464 ethylene dichloride results in decreased expression of LIPG mRNA CTD PMID:28189721 , PMID:28960355 1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol decreases abundance EXP 6480464 LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol CTD PMID:24777581 1-octadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycerol multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol CTD PMID:24777581 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine increases hydrolysis ISO RGD:1321819 6480464 LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine CTD PMID:15953354 1-palmitoyl-2-oleoyl-sn-glycerol decreases abundance EXP 6480464 LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol CTD PMID:24777581 1-stearoyl-2-linoleoyl-sn-glycerol decreases abundance EXP 6480464 LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol CTD PMID:24777581 1-stearoyl-sn-glycero-3-phosphocholine multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin CTD PMID:24777581 17beta-estradiol decreases expression ISO RGD:1321819 6480464 Estradiol results in decreased expression of LIPG mRNA CTD PMID:20106945 17beta-estradiol increases expression ISO RGD:1321819 6480464 Estradiol results in increased expression of LIPG mRNA CTD PMID:31614463 17beta-estradiol multiple interactions ISO RGD:1321819 6480464 [Estradiol co-treated with TGFB1 protein] results in increased expression of LIPG mRNA CTD PMID:30165855 17beta-estradiol 3-benzoate decreases expression ISO RGD:1310740 6480464 estradiol 3-benzoate results in decreased expression of LIPG mRNA CTD PMID:32741896 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1321819 6480464 Tetrachlorodibenzodioxin results in increased expression of LIPG mRNA CTD PMID:21632981 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1310740 6480464 Tetrachlorodibenzodioxin results in increased expression of LIPG mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of LIPG mRNA CTD PMID:25975270 more ... 2-hydroxypropanoic acid increases expression ISO RGD:1321819 6480464 Lactic Acid results in increased expression of LIPG mRNA CTD PMID:30851411 3,3',4,4'-tetrachlorobiphenyl multiple interactions EXP 6480464 3 more ... CTD PMID:19467301 3,3',5,5'-tetrabromobisphenol A increases expression EXP 6480464 tetrabromobisphenol A results in increased expression of LIPG mRNA CTD PMID:25172293 3-chloropropane-1,2-diol increases expression ISO RGD:1310740 6480464 alpha-Chlorohydrin results in increased expression of LIPG mRNA CTD PMID:28522335 4,4'-sulfonyldiphenol increases expression EXP 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of LIPG mRNA CTD PMID:30951980 4,4'-sulfonyldiphenol decreases expression EXP 6480464 bis(4-hydroxyphenyl)sulfone results in decreased expression of LIPG mRNA CTD PMID:33297965 4-hydroxynon-2-enal decreases expression EXP 6480464 4-hydroxy-2-nonenal results in decreased expression of LIPG mRNA CTD PMID:19191707 6-propyl-2-thiouracil increases expression ISO RGD:1310740 6480464 Propylthiouracil results in increased expression of LIPG mRNA CTD PMID:22504374 aflatoxin B1 affects expression ISO RGD:1321819 6480464 Aflatoxin B1 affects the expression of LIPG protein CTD PMID:20106945 aflatoxin B1 decreases expression ISO RGD:1321819 6480464 Aflatoxin B1 results in decreased expression of LIPG mRNA CTD PMID:27153756 aldehydo-D-glucose decreases expression EXP 6480464 Glucose results in decreased expression of LIPG mRNA CTD PMID:17178593 ammonium chloride affects expression ISO RGD:1310740 6480464 Ammonium Chloride affects the expression of LIPG mRNA CTD PMID:16483693 amphetamine decreases expression ISO RGD:1310740 6480464 Amphetamine results in decreased expression of LIPG mRNA CTD PMID:30779732 arachidonic acid multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid CTD PMID:24777581 arachidonic acid decreases abundance EXP 6480464 LIPG gene mutant form results in decreased abundance of Arachidonic Acid CTD PMID:24777581 arsane decreases expression EXP 6480464 Arsenic results in decreased expression of LIPG mRNA CTD PMID:19654921 arsane multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of LIPG mRNA CTD PMID:32045263 arsenic atom decreases expression EXP 6480464 Arsenic results in decreased expression of LIPG mRNA CTD PMID:19654921 arsenic atom multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of LIPG mRNA CTD PMID:32045263 aspartame multiple interactions EXP 6480464 [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of LIPG mRNA CTD PMID:23783067 belinostat multiple interactions ISO RGD:1321819 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA CTD PMID:27188386 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of LIPG mRNA CTD PMID:27195522 benzo[a]pyrene decreases expression ISO RGD:1321819 6480464 Benzo(a)pyrene results in decreased expression of LIPG mRNA CTD PMID:32234424 benzo[a]pyrene decreases methylation ISO RGD:1321819 6480464 Benzo(a)pyrene results in decreased methylation of LIPG 5' UTR, Benzo(a)pyrene results in decreased methylation of LIPG promoter CTD PMID:27901495 benzo[e]pyrene increases methylation ISO RGD:1321819 6480464 benzo(e)pyrene results in increased methylation of LIPG 3' UTR CTD PMID:30157460 bis(2-ethylhexyl) phthalate increases expression EXP 6480464 Diethylhexyl Phthalate results in increased expression of LIPG mRNA CTD PMID:19850644 bis(2-ethylhexyl) phthalate multiple interactions EXP 6480464 PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of LIPG mRNA] CTD PMID:19850644 bisphenol A decreases expression ISO RGD:1310740 6480464 bisphenol A results in decreased expression of LIPG mRNA CTD PMID:25181051 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of LIPG mRNA CTD PMID:32156529 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of LIPG mRNA CTD PMID:30951980 bisphenol A increases methylation ISO RGD:1310740 6480464 bisphenol A results in increased methylation of LIPG gene CTD PMID:28505145 bisphenol F increases expression EXP 6480464 bisphenol F results in increased expression of LIPG mRNA CTD PMID:30951980 cadmium dichloride decreases expression EXP 6480464 Cadmium Chloride results in decreased expression of LIPG mRNA CTD PMID:24982889 calcitriol increases expression ISO RGD:1321819 6480464 Calcitriol results in increased expression of LIPG mRNA CTD PMID:16002434 cholesteryl arachidonate decreases abundance EXP 6480464 LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate CTD PMID:24777581 cholesteryl arachidonate multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate CTD PMID:24777581 cholesteryl linoleate affects abundance EXP 6480464 LIPG gene mutant form affects the abundance of cholesteryl linoleate CTD PMID:24777581 cholesteryl linoleate multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate CTD PMID:24777581 cholesteryl linolenate multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate CTD PMID:24777581 cholesteryl linolenate increases abundance EXP 6480464 LIPG gene mutant form results in increased abundance of cholesteryl linolenate CTD PMID:24777581 cholesteryl myristate multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate CTD PMID:24777581 cholesteryl myristate affects abundance EXP 6480464 LIPG gene mutant form affects the abundance of cholesteryl myristate CTD PMID:24777581 cholesteryl oleate multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate CTD PMID:24777581 cholesteryl oleate increases abundance EXP 6480464 LIPG gene mutant form results in increased abundance of cholesteryl oleate CTD PMID:24777581 cholesteryl palmitate multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate CTD PMID:24777581 cholesteryl palmitate increases abundance EXP 6480464 LIPG gene mutant form results in increased abundance of cholesteryl palmitate CTD PMID:24777581 cholesteryl stearate decreases abundance EXP 6480464 LIPG gene mutant form results in decreased abundance of cholesterol stearate CTD PMID:24777581 choline multiple interactions EXP 6480464 [Dietary Fats co-treated with Choline deficiency] results in increased expression of LIPG mRNA, PANX1 gene mutant form inhibits the reaction [[Dietary Fats co-treated with Choline deficiency] results in increased expression of LIPG mRNA] CTD PMID:29246445 copper(II) sulfate increases expression ISO RGD:1321819 6480464 Copper Sulfate results in increased expression of LIPG mRNA CTD PMID:19549813 crocidolite asbestos decreases expression EXP 6480464 Asbestos, Crocidolite results in decreased expression of LIPG mRNA CTD PMID:29279043 cyclosporin A decreases expression ISO RGD:1321819 6480464 Cyclosporine results in decreased expression of LIPG mRNA CTD PMID:20106945 cyclosporin A affects expression ISO RGD:1321819 6480464 Cyclosporine affects the expression of LIPG mRNA CTD PMID:25562108 D-glucose decreases expression EXP 6480464 Glucose results in decreased expression of LIPG mRNA CTD PMID:17178593 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of LIPG mRNA CTD PMID:21266533 dibutyl phthalate decreases expression ISO RGD:1310740 6480464 Dibutyl Phthalate results in decreased expression of LIPG mRNA CTD PMID:21266533 dichloroacetic acid increases expression EXP 6480464 Dichloroacetic Acid results in increased expression of LIPG mRNA CTD PMID:28962523 dioxygen decreases expression EXP 6480464 Oxygen deficiency results in decreased expression of LIPG mRNA CTD PMID:20880076 dorsomorphin multiple interactions ISO RGD:1321819 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA CTD PMID:27188386 doxorubicin affects expression ISO RGD:1321819 6480464 Doxorubicin affects the expression of LIPG mRNA CTD PMID:29803840 epoxiconazole decreases expression EXP 6480464 epoxiconazole results in decreased expression of LIPG mRNA CTD PMID:35436446 ethanol increases expression ISO RGD:1321819 6480464 Ethanol results in increased expression of LIPG mRNA CTD PMID:28986285 flutamide increases expression ISO RGD:1310740 6480464 Flutamide results in increased expression of LIPG mRNA CTD PMID:21525395 formaldehyde increases expression ISO RGD:1321819 6480464 Formaldehyde results in increased expression of LIPG mRNA CTD PMID:27664576 glucose decreases expression EXP 6480464 Glucose results in decreased expression of LIPG mRNA CTD PMID:17178593 hexadecanoic acid multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Palmitic Acid CTD PMID:24777581 hydroquinone increases expression ISO RGD:1321819 6480464 hydroquinone results in increased expression of LIPG mRNA CTD PMID:31256213 inulin multiple interactions EXP 6480464 [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of LIPG mRNA CTD PMID:36331819 leflunomide increases expression ISO RGD:1321819 6480464 leflunomide results in increased expression of LIPG mRNA CTD PMID:28988120 linoleic acid multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Linoleic Acid CTD PMID:24777581 lipopolysaccharide multiple interactions ISO RGD:1321819 6480464 [Lipopolysaccharides co-treated with resveratrol] results in decreased expression of LIPG mRNA CTD PMID:26667767 methapyrilene increases methylation ISO RGD:1321819 6480464 Methapyrilene results in increased methylation of LIPG 3' UTR CTD PMID:30157460 methimazole increases expression ISO RGD:1310740 6480464 Methimazole results in increased expression of LIPG mRNA CTD PMID:22504374 methylisothiazolinone increases expression ISO RGD:1321819 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of LIPG mRNA CTD PMID:31629900 mitoxantrone affects response to substance ISO RGD:1321819 6480464 LIPG protein affects the susceptibility to Mitoxantrone CTD PMID:16217747 mono(2-ethylhexyl) phthalate decreases expression EXP 6480464 mono-(2-ethylhexyl)phthalate results in decreased expression of LIPG mRNA CTD PMID:22401849 monosodium L-glutamate multiple interactions EXP 6480464 [Fats, Unsaturated co-treated with Sodium Glutamate co-treated with Aspartame] affects the expression of LIPG mRNA CTD PMID:23783067 N-hexadecanoylsphingosine multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of N-palmitoylsphingosine CTD PMID:24777581 N-methylformamide decreases expression EXP 6480464 methylformamide analog results in decreased expression of LIPG mRNA, methylformamide results in decreased expression of LIPG mRNA CTD PMID:17040096 N-Nitrosopyrrolidine decreases expression ISO RGD:1321819 6480464 N-Nitrosopyrrolidine results in decreased expression of LIPG mRNA CTD PMID:32234424 nevirapine decreases expression ISO RGD:1310740 6480464 Nevirapine metabolite results in decreased expression of LIPG mRNA, Nevirapine results in decreased expression of LIPG mRNA CTD PMID:23947594 nickel atom increases expression ISO RGD:1321819 6480464 Nickel results in increased expression of LIPG mRNA CTD PMID:24768652 , PMID:25583101 O-methyleugenol decreases expression ISO RGD:1321819 6480464 methyleugenol results in decreased expression of LIPG mRNA CTD PMID:32234424 oleic acid multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Oleic Acid CTD PMID:24777581 ozone multiple interactions EXP 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of LIPG mRNA, [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of LIPG mRNA CTD PMID:34911549 paracetamol affects expression EXP 6480464 Acetaminophen affects the expression of LIPG mRNA CTD PMID:17562736 paracetamol increases expression ISO RGD:1310740 6480464 Acetaminophen results in increased expression of LIPG mRNA CTD PMID:33387578 paracetamol decreases expression ISO RGD:1321819 6480464 Acetaminophen results in decreased expression of LIPG mRNA CTD PMID:21420995 , PMID:29067470 perfluorohexanesulfonic acid multiple interactions EXP 6480464 PPARA gene mutant form inhibits the reaction [perfluorohexanesulfonic acid results in increased expression of LIPG mRNA] CTD PMID:28049043 perfluorohexanesulfonic acid increases expression EXP 6480464 perfluorohexanesulfonic acid results in increased expression of LIPG mRNA CTD PMID:28049043 perfluorononanoic acid decreases expression ISO RGD:1321819 6480464 perfluoro-n-nonanoic acid results in decreased expression of LIPG mRNA CTD PMID:32588087 perfluorooctane-1-sulfonic acid multiple interactions EXP 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of LIPG mRNA more ... CTD PMID:36331819 perfluorooctanoic acid increases expression ISO RGD:1321819 6480464 perfluorooctanoic acid results in increased expression of LIPG mRNA CTD PMID:23978341 perfluorooctanoic acid increases expression EXP 6480464 perfluorooctanoic acid results in increased expression of LIPG mRNA CTD PMID:28049043 perfluorooctanoic acid multiple interactions EXP 6480464 PPARA gene mutant form inhibits the reaction [perfluorooctanoic acid results in increased expression of LIPG mRNA] CTD PMID:28049043 phenobarbital multiple interactions EXP 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of LIPG mRNA] CTD PMID:19482888 phenobarbital affects expression EXP 6480464 Phenobarbital affects the expression of LIPG mRNA CTD PMID:23091169 phenobarbital increases expression EXP 6480464 Phenobarbital results in increased expression of LIPG mRNA CTD PMID:19482888 phosphatidylcholine increases abundance EXP 6480464 LIPG gene mutant form results in increased abundance of Phosphatidylcholines CTD PMID:24777581 phosphatidylcholine multiple interactions EXP 6480464 [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines CTD PMID:24777581 pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of LIPG mRNA CTD PMID:18301758 more ... pregnenolone 16alpha-carbonitrile decreases expression EXP 6480464 Pregnenolone Carbonitrile results in decreased expression of LIPG mRNA CTD PMID:28903501 progesterone increases expression ISO RGD:1321819 6480464 Progesterone results in increased expression of LIPG mRNA CTD PMID:18070364 quercetin decreases expression ISO RGD:1321819 6480464 Quercetin results in decreased expression of LIPG mRNA CTD PMID:21632981 quinolin-8-ol decreases expression ISO RGD:1321819 6480464 Oxyquinoline results in decreased expression of LIPG mRNA CTD PMID:21632981 rac-lactic acid increases expression ISO RGD:1321819 6480464 Lactic Acid results in increased expression of LIPG mRNA CTD PMID:30851411 resorcinol increases expression ISO RGD:1321819 6480464 resorcinol results in increased expression of LIPG mRNA CTD PMID:22623647 resveratrol multiple interactions ISO RGD:1321819 6480464 [Lipopolysaccharides co-treated with Resveratrol] results in decreased expression of LIPG mRNA, [Plant Extracts co-treated with Resveratrol] results in decreased expression of LIPG mRNA CTD PMID:23557933 , PMID:26667767 SB 431542 multiple interactions ISO RGD:1321819 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA CTD PMID:27188386 silicon dioxide increases expression ISO RGD:1321819 6480464 Silicon Dioxide analog results in increased expression of LIPG mRNA, Silicon Dioxide results in increased expression of LIPG mRNA CTD PMID:25351596 , PMID:25895662 silver atom decreases expression EXP 6480464 Silver results in decreased expression of LIPG mRNA CTD PMID:27131904 silver(0) decreases expression EXP 6480464 Silver results in decreased expression of LIPG mRNA CTD PMID:27131904 sodium arsenite decreases expression ISO RGD:1321819 6480464 sodium arsenite results in decreased expression of LIPG mRNA CTD PMID:20371982 , PMID:29301061 sodium arsenite multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of LIPG mRNA CTD PMID:32045263 sodium fluoride increases expression EXP 6480464 Sodium Fluoride results in increased expression of LIPG protein CTD PMID:28918527 sotorasib multiple interactions ISO RGD:1321819 6480464 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LIPG mRNA CTD PMID:36139627 sunitinib increases expression ISO RGD:1321819 6480464 Sunitinib results in increased expression of LIPG mRNA CTD PMID:31533062 tamoxifen affects expression EXP 6480464 Tamoxifen affects the expression of LIPG mRNA CTD PMID:20937368 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of LIPG mRNA CTD PMID:31919559 thioacetamide increases expression ISO RGD:1310740 6480464 Thioacetamide results in increased expression of LIPG mRNA CTD PMID:34492290 trametinib multiple interactions ISO RGD:1321819 6480464 [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LIPG mRNA CTD PMID:36139627 trichloroethene increases expression ISO RGD:1310740 6480464 Trichloroethylene results in increased expression of LIPG mRNA CTD PMID:33387578 Triptolide decreases expression EXP 6480464 triptolide results in decreased expression of LIPG mRNA CTD PMID:32835833 urethane increases expression ISO RGD:1321819 6480464 Urethane results in increased expression of LIPG mRNA CTD PMID:28818685 valproic acid decreases expression ISO RGD:1321819 6480464 Valproic Acid results in decreased expression of LIPG mRNA CTD PMID:23179753 , PMID:27188386 venlafaxine hydrochloride increases expression ISO RGD:1321819 6480464 Venlafaxine Hydrochloride results in increased expression of LIPG mRNA CTD PMID:16341940 vorinostat decreases expression ISO RGD:1321819 6480464 vorinostat results in decreased expression of LIPG mRNA CTD PMID:27188386 zoledronic acid increases expression ISO RGD:1321819 6480464 zoledronic acid results in increased expression of LIPG mRNA CTD PMID:24714768
